Artificial sweeteners that gel in response to temperature

LAP683AUndetermined Publication Date: 2025-12-19WAKAMOTO PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP683
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-12-26
Filing Date
2018-04-25
Publication Date
2025-12-19

AI Technical Summary

Technical Problem

Current artificial tear compositions, particularly those containing methylcellulose, face challenges in maintaining low viscosity at room temperature while increasing viscosity near body temperature, and they often require refrigeration to prevent gelation, making them unsuitable for portable use and frequent administration.

Method used

An aqueous composition combining two types of methylcellulose with polyethylene glycol and polyvinylpyrrolidone, along with citric acid or its pharmaceutically acceptable salts, which gelates near body temperature but becomes more fluid with gentle shaking, allowing for sol-gel phase transition and easy administration.

Benefits of technology

The composition effectively retains moisture on the ocular surface, protects the cornea, and alleviates corneal epithelial damage, maintaining therapeutic efficacy while being portable and easy to administer without the need for refrigeration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention is a water-soluble solution comprising two types of methylcelluloses, polyethylene glycol, polyvinyl pyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains viscosity upon heating to around body temperature and even after gelation.
Need to check novelty before this filing date? Find Prior Art

Description

Heat-gelling artificial tears

[0001] The present invention relates to an aqueous composition that thickens at temperatures near human body temperature and whose fluidity increases when a force is applied to the thickened composition. More specifically, the present invention relates to a thermally gelling artificial tear solution containing methylcellulose as a main ingredient, which is used to treat dry eye and other conditions.

[0002] Tears are produced in the lacrimal glands located on the outer side of the upper eyelid, moisturizing the surface of the eye before draining through the puncta at the inner corner of the eye and into the back of the nose. Tears were previously thought to have a three-layer structure consisting of an oily layer, an aqueous layer, and a mucin layer, stretching from the surface of the eye toward the cornea. However, in recent years, the concept has shifted to one where there is no partition between the aqueous and mucin layers, and mucin is mixed into the aqueous layer at a concentration gradient. The current concept is that tears have a two-layer structure consisting of an aqueous layer mixed with an oily layer and a mucin layer. Abnormalities in either of these two layers can cause dry eye. Conditions known as "evaporative dry eye," caused by abnormalities in the tear's oily layer, include meibomian gland dysfunction and blepharitis. Conditions known as "aqueous-deficient dry eye," caused by abnormalities in the tear's aqueous layer, include Sjögren's syndrome and Stevens-Johnson syndrome.

[0003] In 2016, the Dry Eye Research Society defined dry eye as "a disease characterized by a decrease in tear film stability due to various factors, resulting in ocular discomfort, visual impairment, and possible ocular surface damage." The primary goal of dry eye treatment is to restore normal tear structure and improve corneal and conjunctival epithelial damage and subjective symptoms. Eye drops currently used to treat dry eye include artificial tears, aqueous eye drops containing sodium hyaluronate, sodium chondroitin sulfate, and flavin adenine dinucleotide, as well as serum and oil-based eye drops. In recent years, dry eye treatments such as diquafosol sodium and rebamipide have also become available. For mild dry eye, over-the-counter eye medications with tear supplementation (eye dryness) are readily available in Japan. The role of artificial tears is to increase tear production by externally replenishing deficient tear fluid. The tear volume has been reported to be 6.5±0.3 μL in normal individuals and 4.8±0.4 μL in dry eye patients. The conjunctival sac has a volume of 20–30 μL, and one drop of eye drops is approximately 50 μL. Therefore, in both normal individuals and dry eye patients, instilling one drop of artificial tears into one eye will fill the conjunctival sac with moisture. Examples of artificial tears include aqueous eye drops containing added inorganic salts. However, these aqueous eye drops are rapidly excreted through the nasolacrimal duct after instillation or evaporate from the ocular surface. Therefore, to maintain moisture on the ocular surface or alleviate subjective symptoms, frequent instillation of two to three drops, five to six times a day, is required (Non-Patent Documents 1–3).

[0004] High-viscosity eye drops containing water-soluble polymers are commercially available to delay the drainage of artificial tears from the ocular surface and to replenish large amounts of moisture. Hypromellose (HPMC), hydroxyethyl cellulose (HEC), or hyaluronic acid and its pharmaceutically acceptable salts are added as thickeners. However, due to the high viscosity of these eye drops, it is known that controlling the amount of drops administered can be difficult and that they can cause discomfort, including blurred vision, after administration.

[0005] Among water-soluble polymers, methylcellulose, a cellulose derivative, is known to be a corneal surface protectant, and 0.5% saline containing methylcellulose provides water retention to the corneal surface and forms a thin film with properties similar to tears (Non-Patent Document 4). It is also known that saline containing 0.6% and 1.2% methylcellulose has been shown to promote corneal epithelial wound healing in pig eyes (Non-Patent Document 5). However, these methylcellulose-containing saline solutions do not confirm the unique thermal gelling property of methylcellulose in solution, and the effects of gelling are not taken into consideration at all.

[0006] Aqueous pharmaceutical compositions containing methylcellulose have been described as using thermally gelling preparations containing methylcellulose, hyaluronic acid, and their pharmaceutically acceptable salts, or thermally gelling artificial tears containing methylcellulose, macrogol 4000, and sodium citrate, which gel at around body temperature to increase tear volume, replenish moisture to the ocular surface, and protect the tear lipid layer (Patent Documents 1 and 2). Meanwhile, thermally gelling aqueous pharmaceutical compositions containing a new quinolone antibacterial agent as an active ingredient and with a sufficiently low gelling temperature have been disclosed. Furthermore, it has been reported that ofloxacin gelling ophthalmic solution 0.3% "Wakamoto" is effective against corneal epithelial disorders (Patent Document 3 and Non-Patent Document 6). The above studies merely confirmed the effectiveness of gelling ophthalmic solutions containing one type of methylcellulose among antibacterial gelling ophthalmic solutions. The aqueous pharmaceutical compositions disclosed in these patent documents are generally intended to be stored at low temperatures because, when stored at room temperature, the compositions gradually gel, losing their characteristic of being easily administered as a liquid before instillation. As mentioned above, artificial tears are typically instilled frequently, but reversible heat-gelling aqueous compositions must be stored at low temperatures, making them unsuitable for portable use. Patent Document 4 discloses aqueous pharmaceutical compositions containing methylcellulose, polyethylene glycol, and sodium citrate, as well as sugar alcohols, lactose, carmellose, or cyclodextrin. These compositions gel at room temperature but rapidly lose viscosity and return to a liquid state upon application of gentle shaking or other weak force, i.e., thixotropic aqueous compositions. Patent Document 5 discloses aqueous compositions containing hydroxyethylcellulose and methylcellulose or hypromellose that do not instantly thicken or gel at temperatures near human body temperature, but rapidly lose viscosity and become more fluid upon application of gentle shaking or other weak force. Improvements have been made to improve product distribution and quality of life, such as portable heat-gelling formulations and aqueous compositions that do not cause a foreign body sensation after administration. However, no aqueous compositions capable of reproducing thixotropic properties through repeated sol-gel phase transitions have been disclosed.

[0007] As described above, there is no known aqueous composition combining different grades of methylcellulose in a specific ratio that gels at around body temperature, but transitions to a sol upon application of a physical stimulus and shows reproducibility.

[0008] Furthermore, there are no known aqueous compositions that combine different grades of methylcellulose in specific ratios and that gel at or near body temperature to provide corneal protection or reduce corneal epithelial damage.

[0009] JP 2003-342197 A JP 2003-95924 A WO 02 / 011734 WO 2005 / 042026 WO 2009 / 001899

[0010] Ophthalmology Care, Winter 2010 Special Edition (Vol. 148), Medica Publishing Co., Ltd., edited by Shigeru Kinoshita et al., pp. 145-147. Ocular Surface Diagnosis and Treatment - Dry Eye -, Medical Aoi Publishing, supervised by Yoshihisa Oguchi. Dry Eye Research Society website (http: / / www.dryeye.ne.jp / ). 17th Revised Japanese Pharmacopoeia Commentary, published by Tokyo Hirokawa Shoten. Journal of Ocular Pharmacology and Therapeutics, Volume 15, Number 1, 1999, 59-63. Clinical Ophthalmology Bulletin 4 (2), 2011, 132-137.

[0011] An object of the present invention is to provide an aqueous ophthalmic composition that maintains a low viscosity near room temperature (e.g., near 25°C) but rapidly increases in viscosity at temperatures near body temperature, thereby enabling the retention of tears on the ocular surface. Another object of the present invention is to provide an aqueous ophthalmic composition for protecting the cornea, reducing corneal epithelial damage, or recovering from corneal damage. Another object of the present invention is to provide use of methylcellulose for preparing an aqueous ophthalmic composition for protecting the cornea, reducing corneal epithelial damage, or recovering from corneal damage.

[0012] The present invention was completed based on the finding that the above-mentioned object can be achieved by combining two or more types of methylcellulose having different specifications (e.g., different viscosities) in an aqueous solution containing methylcellulose, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides the following aqueous ophthalmic compositions: an aqueous ophthalmic composition for protecting the cornea, reducing corneal epithelial damage, or recovering from corneal damage; and use of methylcellulose for preparing an aqueous ophthalmic composition for protecting the cornea, reducing corneal epithelial damage, or recovering from corneal damage. 1. An aqueous ophthalmic composition comprising (A) at least two types of methylcellulose, (B) polyethylene glycol, (C) polyvinylpyrrolidone, and (D) citric acid or a pharmaceutically acceptable salt thereof, and characterized by being capable of gelling. 2. The aqueous ophthalmic composition according to item 1 above, wherein component (A) is two types of methylcellulose. 3. The aqueous ophthalmic composition according to item 2 above, wherein the two types of methylcellulose are contained in a mass ratio of 1:30 to 30:1. 4. 4. The aqueous ophthalmic composition according to any one of items 1 to 3 above, wherein component (A) is methylcellulose having a viscosity of 4 to 400 mPa·s in a 2 w / v% aqueous solution at 20° C. 5. The aqueous ophthalmic composition according to any one of items 1 to 3 above, wherein component (A) is two types selected from the group consisting of methylcelluloses having a viscosity of 4 mPa·s, 15 mPa·s, 25 mPa·s, 100 mPa·s, 400 mPa·s, 1500 mPa·s, or 4000 mPa·s in a 2 w / v% aqueous solution at 20° C. 6. The aqueous ophthalmic composition according to any one of items 1 to 5 above, wherein component (B) is at least one type selected from the group consisting of PEG 8000, PEG 4000, PEG 800, PEG 400, and PEG 300. 7. 7. The aqueous ophthalmic composition according to any one of items 1 to 6 above, wherein component (C) is at least one selected from the group consisting of PVP K17, PVP K25, PVP K30, and PVP K90. 8. The aqueous ophthalmic composition according to items 1 to 7 above, which is a heat-gelling artificial tear solution.9. An aqueous ophthalmic composition for protecting the cornea, reducing corneal epithelial damage, or recovering from corneal damage, comprising (A) at least two types of methylcellulose, (B) polyethylene glycol, (C) polyvinylpyrrolidone, and (D) citric acid or a pharmaceutically acceptable salt thereof. 10. Use of at least two types of methylcellulose in combination with polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof to prepare an aqueous ophthalmic composition for protecting the cornea, reducing corneal epithelial damage, or recovering from corneal damage.

[0013] The aqueous ophthalmic composition of the present invention can be used as a therapeutic agent for corneal epithelial disorders such as dry eye, or as an artificial tear for tear replenishment. In such cases, it is used as an eye drop for application to the eyes of mammals, particularly humans. When administered to a living body such as a human, this composition readily thickens at the body temperature. Furthermore, the composition of the present invention thickens even when placed in a high-temperature environment depending on the region or season. However, because the composition is thixotropic, the fluidity of the composition increases (i.e., it changes to a sol) when gently shaken, and the sol-gel phase transition can be repeated, making it easy to administer to a living body.

[0014] Graph showing gelation temperature in Examples and Comparative Examples of the present invention. Graph showing thixotropy in Examples and Comparative Examples of the present invention. Graph showing responsiveness to heat in Examples and Comparative Examples of the present invention. Graph showing responsiveness to heat in Examples of the present invention. Graph showing gelation behavior (first time) in Examples and Comparative Examples of the present invention. Graph showing reproducibility of gelation (fifth time) in Examples and Comparative Examples of the present invention. Graph showing reproducibility of gelation (tenth time) in Examples and Comparative Examples of the present invention. Graph showing results of evaluation of corneal protective effect in Examples and Comparative Examples of the present invention. Graph showing results of evaluation of corneal protective effect in Examples and Comparative Examples of the present invention. Graph showing results of evaluation of corneal protective effect in Examples and Comparative Examples of the present invention. Graph showing results of evaluation of ocular surface retention in Examples and Comparative Examples of the present invention. Graph showing results of tear volume measurement in Examples and Comparative Examples of the present invention. Graph showing results of evaluation of corneal damage recovery effect in Examples and Comparative Examples of the present invention. Photographs of corneal damage observed 12 days after the start of administration of Examples and Comparative Examples of the present invention.

[0015] (A) At least two types of methylcellulose. The methylcellulose (hereinafter referred to as MC) used in the present invention can be any commercially available pharmaceutical additive. For example, in terms of viscosity, a 2 wt / v% aqueous solution should have a viscosity of 12,000 mPa·s (milliPa·s) or less at 20°C, with 120 mPa·s or less being more preferred. The methoxy group content is preferably in the range of 26 to 33%. MC is further classified by the viscosity of its aqueous solution. For example, commercially available MCs with nominal viscosities of 4, 15, 25, 100, 400, 1500, and 4000 (the numbers indicate the viscosity (unit: milliPascal·second) of a 2 wt / v% aqueous solution at 20°C. Hereinafter, the same applies when simply referring to "viscosity" or "nominal viscosity." For example, a "nominal viscosity of 4" means that a 2 wt / v% aqueous solution has a viscosity of 4 milliPascal·second at 20°C). These MCs are readily available. MCs with nominal viscosities of 4 to 400 are preferred for ease of handling. More preferred are two MCs selected from the group consisting of 4, 15, 25, 100, 400, 1500, and 4000 nominal viscosities. MCs with nominal viscosities of 4, 15, and 400 are even more preferred. Combinations of MCs with nominal viscosities of 4 and 15, MCs with nominal viscosities of 4 and 400, and MCs with nominal viscosities of 15 and 400 are particularly preferred. A combination of MCs with nominal viscosities of 4 and 15 is particularly preferred. The overview, specifications, uses, dosages, and trade names of MCs are described in detail in the Pharmaceutical Additives Dictionary (edited by the Japan Pharmaceutical Additives Association, published by Yakuji Nipposha). MCs are also listed in the 17th Revised Japanese Pharmacopoeia as monographs based on a survey agreement between the three pharmacopoeias of Japan, the United States, and Europe. Most of the MC specifications are common to all three pharmacopoeias. The viscosity of MC can be measured according to the method described in the 17th Edition of the Japanese Pharmacopoeia.

[0016] (B) Polyethylene Glycol Polyethylene glycol (hereinafter also referred to as PEG) used in the present invention is commercially available as a pharmaceutical additive, for example, under the trade names PEG-200, -300, -400, -600, -1000, -1500, -1540, -2000, -4000, -6000, -8000, -20000, -50000, -500000, -2000000 and -4000000 from Wako Pure Chemical Industries, Ltd., under the trade name Macrogol-200, -400, -1500, -4000, -6000 or -20000 from Sanyo Chemical Industries, Ltd., and further, CARBOWAX (registered trademark) PEG These PEGs are sold by Dow Chemical Company under the trade names 200, 300, 400, 540, 600, 1000, 1450, 3350, 4000, 4600, and 8000. The weight-average molecular weight of the PEG used in the base of the present invention is preferably 300 to 50,000, with 300 to 8,000 being particularly preferred. A weight-average molecular weight of 300 or greater is likely to cause a sol-gel phase transition due to body temperature, while a weight-average molecular weight of 50,000 or less is preferred because the viscosity in the liquid state does not become too high. PEGs with a weight-average molecular weight of 4,000 or 8,000 are particularly preferred. It is also possible to adjust the weight-average molecular weight within the above-mentioned optimal range by mixing two or more types of PEG. The overview, specifications, uses, dosage, and trade name of PEG are described in detail in the Pharmaceutical Additives Dictionary (edited by the Japan Pharmaceutical Additives Association, published by Yakuji Nipposha). The outline and specifications of PEG are described in detail in the United States Pharmacopeia (2018 US Pharmacopeia National Formulary, USP41 NF36, hereinafter referred to as USP41(NF36)). The weight-average molecular weights of PEG-400, -4000, -6000, and -20000 can be measured according to the method described in the 17th Edition of the Japanese Pharmacopoeia. The viscosity of PEG with a weight-average molecular weight of 200 to 8000 can be measured according to USP41(NF36), and the viscosity range is specified.

[0017] Polypropylene glycol can be used instead of or in addition to PEG. By incorporating polypropylene glycol, the viscosity of the composition of the present invention can be adjusted to an appropriate range. The polypropylene glycol that can be used in the present invention preferably has a weight-average molecular weight of 200 to 40,000, more preferably 200 to 1,200, even more preferably 200 to 700 due to its high solubility in water, and particularly preferably 200 to 400. The weight-average molecular weight of polypropylene glycol 2000 can be measured according to the method described in Pharmaceutical Excipients Standards 2013 (published by Yakuji Nipposha). Polypropylene glycols are sold, for example, by NOF Corporation under the trade names Uniol (registered trademark) D-200, D-250, D-400, D-700, D-1000, D-1200, D-2000, and D-4000. The weight average molecular weight and kinematic viscosity of the Uniol D series are listed in the General Catalog of Oil and Chemical Products (NOF Corporation, Oil and Chemical Division).

[0018] (C) Polyvinylpyrrolidone The polyvinylpyrrolidone (hereinafter also referred to as PVP) used in the present invention may be any commercially available pharmaceutical additive. Specific examples include PVP K17, PVP K25, PVP K30, and PVP K90. The weight-average molecular weight of the PVP used in the present invention is preferably 2,500 to 250,000, and particularly preferably 20,000 to 150,000. At least one selected from the group consisting of PVP K17, PVP K25, PVP K30, and PVP K90 is preferred. PVP K25 is particularly preferred. The overview, specifications, uses, dosage, and trade name of PVP are described in detail in the Pharmaceutical Additives Dictionary (edited by the Japan Pharmaceutical Additives Association, published by Yakuji Nipposha). PVP K25, PVP K30, and PVP K90 are listed as povidone in the 17th edition of the Japanese Pharmacopoeia. Povidone is listed in the 17th edition of the Japanese Pharmacopoeia as a monograph based on a survey agreement between the three pharmacopoeias of Japan, the United States, and Europe. Most of the specifications for povidone are common to all three pharmacopoeias. In this document, PVP K25 may be referred to as PVP k25.

[0019] (D) Citric Acid or a Pharmacologically Acceptable Salt Thereof. Citric acid used in the present invention includes citric acid hydrate and pharmaceutically acceptable salts of citric acid. Examples of the pharmaceutically acceptable salts of citric acid include sodium salts and potassium salts. Examples of sodium salts include sodium citrate hydrate (also known as sodium citrate (JP), hereinafter referred to as sodium citrate), sodium dihydrogen citrate, and disodium citrate. Examples of potassium salts include potassium citrate (potassium citrate monohydrate). The overview, specifications, and uses of sodium citrate as sodium citrate hydrate are described in detail in the 17th Edition of the Japanese Pharmacopoeia. Furthermore, the overview and specifications of sodium citrate dihydrate are described in detail in USP 41 (NF36).

[0020] The total concentration of MC in the aqueous ophthalmic composition of the present invention is preferably 0.2 to 5 w / v%. A total concentration of MC of 0.2 w / v% or more is preferred because the composition of the present invention is likely to gel at the temperature of the ocular surface. A total concentration of MC of 5 w / v% or less is also preferred because the viscosity can be adjusted to a range that is easy to handle. The total concentration of MC is more preferably 0.5 w / v% or more, and even more preferably 1 w / v% or more. The total concentration is also more preferably 4 w / v% or less, and even more preferably 3 w / v% or less.

[0021] In an embodiment of the ophthalmic composition of the present invention, three or more MCs of different specifications can be mixed. Compositions containing three or more MCs are preferred because they thicken relatively quickly at temperatures near human body temperature (34-38°C) compared to compositions containing a single MC. Compositions containing two MCs are even more preferred because their viscosity can be easily adjusted to allow storage as a liquid (sol) at room temperature (1-30°C). When two MCs are used in combination, the concentration of one MC in the composition is preferably 0.1-3 w / v%. An MC concentration of 0.1 w / v% or higher is preferred because it thickens at temperatures near human body temperature (34-38°C). Furthermore, an MC concentration of 3 w / v% or lower is preferred because it facilitates the preparation of an aqueous solution with low viscosity at room temperature (1-30°C). A concentration of 0.1 w / v% or higher is more preferred, and even more preferred is 0.2 w / v% or higher. A concentration of 2.5 w / v% or higher is even more preferred. When two types of MC are used in combination, MCs of different specifications (preferably viscosities) are preferably mixed in a mass ratio of 1:30 to 30:1, more preferably 1:24 to 24:1, and even more preferably 1:4 to 4:1. In particular, it is preferable to use a combination of an MC with a nominal viscosity of 4 and an MC with a nominal viscosity of 15, a combination of an MC with a nominal viscosity of 4 and an MC with a nominal viscosity of 400, or a combination of an MC with a nominal viscosity of 15 and an MC with a nominal viscosity of 400 in the above mass ratio. It is particularly preferable to use a combination of an MC with a nominal viscosity of 4 and an MC with a nominal viscosity of 15 in the above mass ratio, and it is particularly preferable to use a combination of an MC with a nominal viscosity of 4 and an MC with a nominal viscosity of 15 in the above mass ratio.

[0022] In an embodiment of the aqueous ophthalmic composition of the present invention, the following concentration ranges are more preferred for components other than MC. The PEG concentration is in the range of 0.5 to 4.0 w / v%. Concentrations below 0.5 w / v% are impractical due to the difficulty in forming a localized gel, and concentrations above 4 w / v% are undesirable due to the low gelling temperature. The polypropylene glycol concentration is in the range of 0.1 to 4 w / v%, and concentrations above 4 w / v% are undesirable due to the risk of eye irritation. The PVP concentration is in the range of 0.5 to 4.0 w / v%, and concentrations below 0.5 w / v% are impractical due to the difficulty in forming a localized gel, and concentrations above 4 w / v% are undesirable due to the high viscosity of the sol. The citric acid concentration is in the range of 1.0 to 4.0 w / v%, and concentrations below 1.0 w / v% are impractical due to the difficulty in forming a localized gel, and concentrations above 4 w / v% are undesirable due to the risk of eye irritation.

[0023] The composition of the present invention most preferably contains: (A) MC having a nominal viscosity of 4 and MC having a nominal viscosity of 15 in a mass ratio of 1:4 to 4:1, in an amount that results in a total concentration of 0.2 to 5 w / v%, (B) 0.5 to 4.0 w / v% PEG having a weight-average molecular weight of 4000 or 8000, (C) 0.5 to 4.0 w / v% PVP K25, and (D) 1.0 to 4.0 w / v% citric acid or its sodium salt. The pH adjuster of this composition is preferably sodium hydroxide or sulfuric acid.

[0024] Since it is desirable for the aqueous ophthalmic composition of the present invention to gel at a temperature close to the body temperature of a mammal, the gelation temperature (the temperature at which a phase transition from sol to gel occurs) of the aqueous ophthalmic composition of the present invention is preferably about 30°C to 40°C, more preferably 34°C to 40°C. The aqueous ophthalmic composition of the present invention can be stored at room temperature (1°C to 30°C) as a liquid preparation that can be administered immediately. The gelation temperature can be finely adjusted by adjusting the concentrations of the components (B) to (D).

[0025] The ophthalmic composition of the present invention can be used as a therapeutic agent for corneal epithelial disorders such as dry eye. The aqueous ophthalmic composition of the present invention can also be used as an artificial tear for replenishing tears in keratoconjunctivitis sicca and aqueous tear hypocalcemia, as an artificial tear for replenishing tears in the discomfort caused by contact lens wear, dry eyes, eye fatigue, and blurred vision associated with tear deficiency, and as an artificial tear for replenishing tears in the stinging and irritation caused by dry eyes. The aqueous ophthalmic composition of the present invention can also be used as an artificial tear for suppressing corneal dryness and protecting the cornea, or as an artificial tear for increasing tear volume. The aqueous ophthalmic composition of the present invention can also be used as an artificial tear that remains on the ocular surface and alleviates corneal epithelial disorders. The aqueous ophthalmic composition of the present invention can also be used as an artificial tear that can quickly recover from corneal damage and thereby recover from corneal disorders.

[0026] The aqueous ophthalmic composition of the present invention may contain, as an active ingredient for dry eye or as an active ingredient for artificial tears, inorganic salts such as sodium chloride, potassium chloride, calcium chloride, sodium bicarbonate, sodium carbonate, dry sodium carbonate, magnesium sulfate, sodium hydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate, as well as sugars such as glucose, amino acids such as potassium L-aspartate, magnesium L-aspartate, magnesium and potassium L-aspartate (an equal mixture), aminoethylsulfonic acid (hereinafter also referred to as taurine), sodium chondroitin sulfate, and pharmaceutically acceptable salts thereof, polyvinyl alcohol, hyaluronic acid and pharmaceutically acceptable salts thereof, and polymeric compounds such as hydroxyethyl cellulose and hypromellose (hydroxypropyl methylcellulose). The amount of these active ingredients is not particularly limited, as long as the concentration is such that the expected medicinal effect is obtained.

[0027] The aqueous ophthalmic composition of the present invention is usually adjusted to a pH of 3 to 10, and preferably adjusted to a pH of 5 to 8, particularly in terms of preventing eye irritation. Various commonly added pH adjusters may be used to adjust the pH of the artificial tears of the present invention. Examples include acids, bases, amino acids, etc. Examples of acids include hydrochloric acid, sulfuric acid, phosphoric acid, boric acid, acetic acid, lactic acid, gluconic acid, ascorbic acid, etc. Examples of bases include potassium hydroxide, calcium hydroxide, sodium hydroxide, magnesium hydroxide, monoethanolamine, diethanolamine, triethanolamine, etc. Examples of amino acids include glycine, histidine, epsilon-aminocaproic acid, etc.

[0028] The aqueous ophthalmic composition of the present invention may contain, as necessary, pharmaceutically acceptable tonicity agents, solubilizers, preservatives, antiseptics, etc. Examples of tonicity agents include sugars such as xylitol, mannitol, and glucose, propylene glycol, glycerin, sodium chloride, and potassium chloride. Examples of solubilizers include polysorbate 80, polyoxyethylene hydrogenated castor oil, and cyclodextrin.

[0029] Preservatives that can be used include ionic preservatives such as benzalkonium chloride (hereinafter also referred to as BAC), benzethonium chloride, and cetylpyridinium chloride; biguanide preservatives such as chlorhexidine gluconate, chlorhexidine hydrochloride, 1,1-dimethylbiguanide hydrochloride, polyhexamethylene biguanide, alexidine, hexetidine, and N-alkyl-2-pyrrolidinone; polyquaternium preservatives such as polidronium chloride; parabens such as methyl parahydroxybenzoate, propyl parahydroxybenzoate, and butyl parahydroxybenzoate; alcohols such as chlorobutanol, phenylethyl alcohol, bronopol, and benzyl alcohol; and organic acids and their salts such as sodium dehydroacetate, sorbic acid, and potassium sorbate. Benzalkonium chloride, a highly versatile preservative for ophthalmic solutions, has the general formula [CHCHN(CHR)]Cl. In this formula, R represents an alkyl group. In the composition of the present invention, benzalkonium chloride sold by Okami Chemical Industry Co., Ltd. was used.

[0030] Other additives include thickeners such as hydroxyethyl cellulose, polyvinyl alcohol, propylene glycol, diethylene glycol, hyaluronic acid and its pharmaceutically acceptable salts, sodium chondroitin sulfate or sodium polyacrylate, stabilizers such as EDTA (ethylenediaminetetraacetic acid) and its pharmaceutically acceptable salts, tocopherol and its derivatives, and sodium sulfite.

[0031] The method for producing the aqueous ophthalmic composition of the present invention is not particularly limited. For example, methylcellulose, polyethylene glycol, polyvinylpyrrolidone, and citric acid are dispersed in hot water at approximately 60 to 70°C and cooled to below 10°C. If necessary, inorganic salts, other active ingredients, additives, etc. are added and dissolved, and the mixture is thoroughly mixed. The pH of the resulting solution is adjusted with a pH adjuster as needed, and the solution is diluted with sterile purified water to prepare the aqueous ophthalmic composition of the present invention. After sterilization, the composition is filled into a plastic eye drop bottle and ready for use. The aqueous ophthalmic composition of the present invention is used as an eye drop for application to the eyes of mammals, particularly humans.

[0032] The present invention will be explained in more detail below by way of examples, but the present invention is not limited to these examples.

[0033] Test Example 1A: Methylcellulose (Metolose (registered trademark) SM-4 and SM-15, manufactured by Shin-Etsu Chemical Co., Ltd.), polyethylene glycol (CARBOWAX (registered trademark) PEG 8000, manufactured by The Dow Chemical Company), polyvinylpyrrolidone (PVP k25), and sodium citrate were mixed in predetermined amounts and added to sterile purified water heated to 60-70°C. The mixture was then dispersed by stirring. After confirming uniform dispersion, the mixture was cooled to 10°C or below while stirring. After confirming that the mixture was entirely clear, a predetermined amount of benzalkonium chloride was added and dissolved. The pH was then adjusted to 7.0 with 1 M aqueous sodium hydroxide or 1 M aqueous sulfuric acid, and the mixture was diluted to the predetermined volume with sterile purified water to prepare aqueous ophthalmic compositions of the present invention (Examples 1 and 2). The formulations are shown in Table 1. In the table, the amounts of each component are all expressed in w / v %.

[0034]

[0035] As comparative examples, Examples 3 and 4 of Patent Document 1, Example 7 of Patent Document 4, and Example 5 of Patent Document 3 were prepared by the methods described in each patent document (Comparative Examples 1 to 4). The formulations are shown in Table 2.

[0036]

[0037] To investigate the relationship between temperature and viscosity for the Examples and Comparative Examples shown in Tables 1 and 2, the viscosity behavior of each aqueous composition was observed. The viscosity of the compositions of Examples 1 and 2 and Comparative Examples 1 to 4 was measured at 20°C to 40°C to evaluate the relationship between temperature and viscosity. Viscosity was measured using an Anton Paar rheometer (Modular Compact Rheometer 102). Approximately 1 mL of the prepared composition of the present invention was placed between a parallel plate with a diameter of approximately 50 mm and a temperature-control Peltier element. The gap between the Peltier element and the parallel plate was set to 0.5 mm. The sample was cooled to 5°C for 5 minutes before the start of measurement. From the start of measurement, the temperature was gradually increased to each measurement temperature. Each measurement temperature was maintained for 240 seconds before viscosity measurement. The results are shown in Figure 1.

[0038] The compositions of Examples 1 and 2 of the present invention maintained low viscosity up to 32°C and rapidly increased viscosity between 34°C and 40°C. In Comparative Example 1, the viscosity increased slightly between 34°C and 40°C, but the viscosity remained low overall. In Comparative Examples 2 and 3, the viscosity increased from 32°C, and in Comparative Example 4, the viscosity suddenly increased around 25°C. Since the gelation temperatures of Comparative Examples 2 and 3 are closer to room temperature than the compositions of the present invention, and Comparative Example 4 significantly increased in viscosity at room temperature, it was shown that storage at room temperature is difficult. On the other hand, it was shown that the aqueous ophthalmic composition of the present invention can be stored as a liquid preparation that can be administered immediately at room temperature (1 to 30°C).

[0039] Test Example 1B Examples 4 to 39 were prepared in the same manner as in Examples 1 and 2 above. Methylcellulose (SM-4, SM-15, and SM-400), polyethylene glycol (PEG8000, PEG4000, PEG400, and PEG300), polyvinylpyrrolidone (PVP k25, PVP k30, and PVP k90), and sodium citrate were mixed in predetermined amounts. When preparing the Examples in Table 6, a predetermined amount of boric acid or hyaluronic acid was further added. The mixture was added to sterile purified water heated to 60-70°C and dispersed by stirring. After confirming uniform dispersion, the mixture was cooled to below 10°C while stirring. After confirming that the mixture was entirely clear, the other components shown in Tables 3 to 7 were added in predetermined amounts and dissolved. Furthermore, the pH was adjusted with 1 M aqueous sodium hydroxide solution or 1 M aqueous sulfuric acid solution, and the mixture was diluted to the predetermined volume with sterile purified water to prepare the aqueous ophthalmic composition of the present invention. Comparative Example A was prepared in the same manner as in Example 1. The formulations are shown in Tables 3 to 7.

[0040] The viscosity of the compositions of Examples 4 to 39 and Comparative Example A was measured at 20°C to 40°C to evaluate the relationship between temperature and viscosity. Viscosity was measured using an Anton Paar rheometer (Modular Compact Rheometer 102). Approximately 1 mL of the prepared composition of the present invention was placed between a parallel plate with a diameter of approximately 50 mm and a temperature-control Peltier element. The gap between the Peltier element and the parallel plate was set to 0.5 mm. Before starting the measurement, the sample was cooled to 5°C for 5 minutes. After starting the measurement, the temperature was gradually increased to each measurement temperature. Each measurement temperature was maintained for 240 seconds before the viscosity was measured. The results are shown in Tables 3 to 7.

[0041]

[0042]

[0043]

[0044]

[0045]

[0046] Tables 3 to 7 show that the compositions of Examples 4 to 39 of the present invention maintained low viscosity up to 32°C and rapidly increased in viscosity between 34°C and 40°C. Table 3 demonstrates that the compositions of the present invention can be prepared regardless of the type of MC and exhibit thermal gel properties. Comparing Example 8 with Example 9 in Table 3, it is clear that the viscosity at low temperatures increases as the proportion of MC with a higher nominal viscosity increases. Table 4 demonstrates that the compositions of the present invention can be prepared regardless of the type or weight-average molecular weight of PVP and exhibit thermal gel properties. Comparing Example 13 with Example 14 in Table 4, the composition with a lower sodium citrate concentration exhibited a more gradual increase in viscosity between 34 and 40°C. Comparing Example 12 with Example 13 in Table 4, the composition with a lower polyethylene glycol concentration exhibited a more gradual increase in viscosity between 34 and 40°C. Comparing Example 13 with Example 15 in Table 4, the composition with a lower PVP concentration exhibited a more gradual increase in viscosity between 34 and 40°C. Table 5 clearly shows that various preservatives can be added to the composition of the present invention without affecting the thermal gel properties. Table 6 clearly shows that acids such as boric acid, thickeners such as hyaluronic acid, bases such as trometamol, and amino acids such as taurine can be added to the composition of the present invention without affecting the thermal gel properties. Table 6 also shows that the composition of the present invention can be prepared and has thermal gel properties regardless of the type or weight-average molecular weight of polyethylene glycol. Table 7 clearly shows that various inorganic salts can be added to the composition of the present invention without affecting the thermal gel properties.

[0047] Table 4 clearly shows that sodium citrate and polyethylene glycol affect the increase in viscosity due to heat in the compositions of the present invention. Table 4 also clearly shows that PVP affects the increase in viscosity due to heat, although not as much as sodium citrate or polyethylene glycol. Table 5 demonstrates that preservatives can be added without limitation, demonstrating that the present invention is suitable for aqueous pharmaceutical compositions. Tables 6 and 7 demonstrate that the compositions of the present invention are suitable for artificial tear compositions. Tables 3 to 7 demonstrate that the compositions of the present invention can be stored at room temperature (1 to 30°C) as ready-to-administer solutions. Tables 3 to 7 suggest that the compositions of the present invention are suitable for aqueous ophthalmic compositions, and that they respond to the temperature of the ocular surface after administration, instantly thicken, and have retention properties.

[0048] Test Example 1C Examples 40 to 52 were prepared in the same manner as in Examples 1 and 2, and their viscosities were measured at 20° C. to 40° C. The formulations and measurement results are shown in Table 8.

[0049]

[0050] Examples 40, 42, and 46 have low viscosities around 20 to 32° C., but the viscosity rises near body temperature at 36 to 40° C. Examples 49, 51, 52, and 53 have low viscosities around 30 to 34° C., but the viscosity rises sharply at 38 and 40° C. The viscosity behavior observed in the viscosity measurement of this test shows a similar viscosity transition to the other examples of the present invention, and therefore Examples 40 to 52 also possess the characteristics of the present invention.

[0051] Test Example 2: Thixotropy during gelation was investigated for Example 2 shown in Table 1 and Comparative Examples 2 to 4 shown in Table 2. For the compositions of Example 2 and Comparative Examples 2 to 4, the relationship between shear stress and strain was determined for the gelled compositions using an Anton Paar rheometer (Modular Compact Rheometer 102). Thixotropy was evaluated if there was a point at which the shear stress and strain relationship was no longer proportional to the shear stress. Approximately 1 mL of the prepared compositions of the present invention and comparative examples was placed between a parallel plate with a diameter of approximately 50 mm and a temperature-control Peltier element. The gap between the Peltier element and the parallel plate was set to 0.5 mm. The measurement sample was cooled at 5°C for 5 minutes before the start of measurement. It was then maintained at 36°C for approximately 10 minutes after the start of measurement. After maintaining the sample at 25°C for 240 seconds, the strain was measured by vibration measurement at a frequency of 1 Hz and a shear stress ranging from 0.01 to 10 Pa. The results are shown in Figure 2.

[0052] The results showed that the compositions of the present invention, Examples, and Comparative Examples 2 and 3, all had a point (yield stress) where the stress and strain were no longer proportional, indicating that they exhibited thixotropy. Comparative Example 4 did not exhibit thixotropy under the test conditions, indicating that it did not exhibit thixotropy.

[0053] Test Example 3A: For Examples 1 and 2 shown in Table 1 and Comparative Examples 1 to 3 shown in Table 2, the viscosity was measured by repeatedly heating and cooling over a fixed period of time to evaluate reproducibility. The change in viscosity of the composition of the present invention, Example 2, was evaluated when the temperature was repeatedly adjusted between 20°C and 36°C. The viscosity was measured using an Anton Paar rheometer (Modular Compact Rheometer 102). Approximately 1 mL of the prepared composition of the present invention was placed between a parallel plate with a diameter of approximately 50 mm and a temperature-control Peltier element. The gap between the Peltier element and the parallel plate was set to 0.5 mm. The measurement sample was cooled at 5°C for 10 minutes before starting the measurement. After starting the measurement, the sample was heated to 36°C and held there for 240 seconds, after which the viscosity was measured. Then, the sample was cooled to 20°C and held there for 240 seconds, after which the viscosity was measured. This 36°C and 20°C cycle was repeated four and a half times. Comparative Example 4 had an extremely high viscosity at 36°C, making it impossible to measure under the same conditions as the other samples. The results of Examples 1 and 2 and Comparative Examples 1 to 3 are shown in FIG.

[0054] The compositions of the present invention and Examples 1 and 2 showed an increase in viscosity at 36°C of 300 to 600 mPa·s in the second to fifth cycles, and a viscosity of 100 mPa·s or less at 20°C. The compositions maintained their heat responsiveness even after four or more cycles of heating and cooling. It was shown that the viscosity increase at 36°C of the compositions of the present invention remained stronger than that of Comparative Examples 1 to 3.

[0055] <Test Example 3B> For Examples 9 and 10 shown in Table 3, the viscosity was measured by repeating heating and cooling for a certain period of time, and reproducibility was evaluated. The test procedure was the same as in Test Example 3A. The results are shown in Figure 4.

[0056] The test results of Test Example 3B showed that the examples of the present invention maintained their thermal responsiveness even after repeated heating and cooling operations.

[0057] Test Example 4 The relationship between temperature and solution state (sol and gel) for Example 2 shown in Table 1 and Comparative Examples 1 to 4 shown in Table 2 was examined to determine the gelation reproducibility of each aqueous composition. The relationship between the solution state (sol and gel) when the temperature of the compositions of Example 2 and Comparative Examples 1 to 4 was raised from 30°C to 36°C, and the gelation reproducibility after the gel structure was broken down at 30°C were evaluated. The storage modulus (G') and loss modulus (G''), which are indicators of gelation, were measured by vibration measurement using an Anton Paar rheometer (Modular Compact Rheometer 102), and the loss tangent (tan(δ)) was calculated using the formula G'' / G'. Generally, a value of tan(δ) > 1 is considered to be a sol, and a value of tan(δ) < 1 is considered to be a gel (Gel Control - Suppressing Gelation by Properly Making Gels -, June 2009, published by Johokki Co., Ltd.). Approximately 1 mL of each of the prepared samples from the Examples and Comparative Examples of the present invention was placed between a parallel plate approximately 50 mm in diameter and a temperature-control Peltier element. The gap between the Peltier element and the parallel plate was set to 0.5 mm. The measurement sample was cooled at 5°C for 10 minutes before the start of measurement. The sample was heated to 30°C in approximately 1 minute and held there for approximately 30 seconds. Oscillatory measurements were performed under test conditions of a frequency of 1 Hz and a strain of 5%, and then the sample was heated to 36°C in approximately 30 seconds and maintained at that temperature for approximately 150 seconds. The gel structure was then broken down by rotating the parallel plate at 30°C and a shear stress of 10 Pa. Measurements were again performed while heating to 36°C, and these procedures were repeated 10 times. The gelation behavior in the first run and the results of the fifth and tenth runs for evaluating gelation reproducibility are shown in Figures 5 to 7.

[0058] In the first gelation measurement, Comparative Example 4 gelled the earliest, with a tan (δ) < 1. Subsequently, Comparative Example 3, Example 2, and Comparative Example 2 gelled in that order, with Comparative Example 1 showing no gelation within this time frame. The order of gelation roughly matched the viscosity at 36°C of Test Example 1. In the evaluation of gelation reproducibility, Comparative Examples 1 to 4 showed a worsening of the transition to a sol with each iteration. Although the transition to a sol in Example 2 weakened, it maintained a sol state for a longer time than the comparative examples, even after the 10th iteration. These results demonstrate that gelation reproducibility can be improved by mixing two types of methylcellulose in an appropriate ratio in accordance with the present invention.

[0059] The results of Test Examples 3A, 3B and 4 showed that the features of the present invention can be obtained by preparing various mixtures of MCs having different nominal viscosities.

[0060] Test Example 5A Evaluation of Corneal Protective Effect (1) Sample Solutions Example 3, Comparative Example 5, and Comparative Example 6 in Table 9 were prepared in the same manner as in Test Example 1. As a control, physiological saline (Hikari Pharmaceutical Co., Ltd.) (hereinafter also referred to as saline) was added.

[0061]

[0062] (2) Test Method: Pigmented domestic rabbits (strain: Kbt: Dutch, weighing 1.5-2.0 kg at time of delivery, Biotech) were euthanized and corneas were harvested (n=3). The harvested corneas were then dried in an incubator at 35°C for 40 minutes. Immediately after the start of drying, 10 μL of each of Example 3 stored at room temperature, saline, and Comparative Examples 5 and 6 stored at 5°C and returned to room temperature immediately before use (60 μL total) was dropped onto the harvested corneas at 1-minute intervals. After drying, the corneas were washed with saline, stained with 1% methylene blue (Nacalai Tesque), and immersed overnight in 400 μL of extraction solution (acetone (Wako Pure Chemical Industries): saturated sodium sulfate (Wako Pure Chemical Industries) aqueous solution = 7:3, volume ratio) to extract any methylene blue remaining in the corneas. The absorbance of each extraction solution at 660 nm was measured. The results are shown in Figure 8.

[0063] The absorbance of Example 3 of the present invention was lower than that of Comparative Examples 5 and 6 or physiological saline.

[0064] The results of Test Example 5A showed that Example 3 of the present invention has the characteristic of suppressing corneal dryness more than saline or existing thermally gelling preparations such as Comparative Examples 5 and 6. This suggests that the composition of the present invention has a corneal protective effect.

[0065] Test Example 5B: Evaluation of Corneal Protective Effect 2 (1) Sample Solutions Comparative Example 5 in Table 9, Example 17 in Table 4, and Example 32 in Table 6 were prepared in the same manner as in Test Example 1. Physiological saline (Hikari Pharmaceutical) was added as a control.

[0066] (2) Test Method: Pigmented domestic rabbits (strain: Kbt: Dutch, weight at time of delivery: 1.5-2.0 kg, Biotech) were euthanized and corneas were harvested. Then, 150 μL each of Example 17, Example 32, and Comparative Example 5 was dropped onto the harvested corneas, and the corneas were dried in an incubator at 35°C for 40 minutes. After drying, the corneas were washed with saline, stained with 1% methylene blue (Nacalai Tesque), and immersed overnight or more in 400 μL of extraction solution (acetone (Wako Pure Chemical Industries): saturated sodium sulfate (Wako Pure Chemical Industries) aqueous solution = 7:3, volume ratio) to extract the methylene blue remaining in the corneas. The absorbance of each extraction solution at 660 nm was measured. The results are shown in FIG. 9.

[0067] Examples 17 and 32 of the present invention exhibited lower absorbance than Comparative Example 5 or physiological saline.

[0068] The results of Test Example 5B showed that the Examples of the present invention have the characteristic of suppressing corneal dryness more than existing thermally gelling preparations such as saline or Comparative Example 5. This suggests that the composition of the present invention has a corneal protective effect.

[0069] Test Example 6: Comparison of corneal protective effects between the present invention and existing products (1) As a sample solution example, Example 3 in Table 9 was prepared in the same manner as Test Example 1. As a comparative example, SYSTANE (registered trademark) ULTRA manufactured by Novartis Pharma K.K. was used as Comparative Example A. SYSTANE (registered trademark) GEL DROPS manufactured by the same company was also used as Comparative Example B. Physiological saline (Hikari Pharmaceutical) was added as a control.

[0070] (2) Test Method: White rabbits (strain: Kbs:JW, body weight 3.5 kg or more, Kitayama Labes) were euthanized, and corneas (n = 3 to 7) were collected. Then, 150 μL of saline, Example 3, Comparative Example A, and Comparative Example B were dropped onto the corneas. After the dropwise ...

[0071] The absorbance of Example 3 of the present invention was lower than that of Comparative Example A, and was equal to or higher than that of Comparative Example B.

[0072] The results of Test Example 6 suggest that the aqueous ophthalmic composition of the present invention has the same or better preventive effect on ophthalmic disorders as the non-viscous aqueous preparation.

[0073] Test Example 7 Comparison of Ocular Surface Retention Between the Present Invention and a Commercially Available Product (1) As a sample solution example, Example 2 in Table 1 was prepared in the same manner as in Test Example 1 and filled into an eye drop bottle. As comparative examples, Comparative Examples A and B were used in the same manner as in Test Example 6. Fluorescite (registered trademark) intravenous injection (500 mg) was added to these sample solutions to a concentration of 1 mg / mL.

[0074] (2) Test Method: The eyelids of albino rabbits (strain: Kbs:JW, Kitayama Labes) were gently separated from the eyeball, and 30 μL of each of Example 2, Comparative Example A, and Comparative Example B was instilled onto the cornea. The upper and lower eyelids were gently pinched together and the rabbits were forcibly closed for 30 seconds. Thirty minutes after instillation, the ocular surface was thoroughly rinsed with 100 μL of saline, and the rinse solution was collected and used as a sample. Simultaneously, the ocular surface rinse solution was collected after forced blinking following instillation, using the following procedure. The eyelids were gently separated from the eyeball, and 30 μL of each solution was instilled onto the cornea. The rabbits were then forcibly closed for 30 seconds by gently pinching both upper and lower eyelids. The rabbits were then forcibly blinked once every 10 seconds. Thirty minutes after instillation, the ocular surface was thoroughly rinsed with 100 μL of saline, and the rinse solution was collected and used as a sample. The fluorescence of each sample was measured at 480 nm (excitation wavelength) and 520 nm (absorption wavelength), and the fluorescent dye concentration was calculated. The results are shown in Figure 11.

[0075] When the fluorescent dye concentrations in the ocular surface cleaning solutions were compared, Example 2 of the present invention showed a fluorescent dye concentration equivalent to that of Comparative Example A, and a higher fluorescent dye concentration than Comparative Example B, regardless of blinking.

[0076] The results of Test Example 7 suggest that the composition of the present invention is superior to aqueous solution preparations in terms of retention on the ocular surface.

[0077] <Test Example 8: Measurement of tear volume>

[0078] (1) As an example of a sample solution, Example 2 in Table 1 was prepared in the same manner as in Test Example 1 and filled into an eye drop bottle. As a control, phosphate-buffered saline (GIBCO (registered trademark) PBS buffers, Life Technologies Corporation) was used. A predetermined amount of benzalkonium chloride [alkyl group carbon number: 14] (benzyldimethyltetradecylammonium chloride hydrate, Tokyo Chemical Industry Co., Ltd.) was dissolved in a small amount of ethanol, and then the solution was diluted with saline to prepare a 0.1 (w / v)% BAC solution.

[0079] (2) Test Method: 20 μL of 0.1 (w / v)% BAC solution was administered twice daily (morning and evening) in a microtube to both eyes of albino rabbits (strain: Kbs:JW, Kitayama Labes) for two consecutive weeks. 30 μL of Example 2 or phosphate-buffered saline was administered to both eyes three times daily for two consecutive weeks, every three hours between morning and evening, shifting the administration time from the above. Example 2 was administered using an eye dropper bottle. Phosphate-buffered saline was administered using a micropipette. Tear fluid was collected using Schirmer's test strips (Ayumi Pharmaceutical Co., Ltd.) before the start of the test and after one and two weeks. The results are shown in FIG. 12 and Table 10.

[0080]

[0081] In the test substance-untreated group, which was not administered either the Example or the control, a decrease in tear production was observed after two weeks. In the phosphate-buffered saline-treated group, a slight increase in tear production was observed after two weeks. On the other hand, in the group administered Example 2 of the present invention, an increase in tear production over time was observed.

[0082] The results of Test Example 8 revealed that daily administration of Example 2 suppressed the decrease in tear production caused by instillation of an aqueous BAC solution and further increased tear production.

[0083] Test Example 9: Effect on corneal damage

[0084] (1) Example 3 in Table 9 was prepared as a sample solution example in the same manner as in Test Example 1. Physiological saline (Otsuka Saline Injection (500 mL) (registered trademark), Otsuka Pharmaceutical Co., Ltd.) was used as a control. Systané (registered trademark) Ultra, manufactured by Novartis Pharma, was used as Comparative Example A. A predetermined amount of benzalkonium chloride (Tokyo Chemical Industry Co., Ltd.) was dissolved in a small amount of ethanol, and then the solution was diluted with physiological saline to prepare a 0.1 (w / v)% BAC solution.

[0085] (2) Test Method: This test method was based on the method by Yuqiu Zhang et al. (Drug and Chemical Toxicology 2016.39(4) 455-460). Three times a day (every 4 hours from morning to evening), 20 μL of 0.1 (w / v)% BAC solution was administered daily using a micropipette into both eyes of albino rabbits (strain: Kbs: JW, Kitayama Labes). The administration period was 42 days, including the day of administration. The degree of corneal surface damage was observed before and after 42 days of administration using a portable slit lamp, Kowa SL-17 (manufactured by Kowa Co., Ltd., hereafter referred to as SL-17). After 42 days of administration of 0.1 (w / v)% BAC solution, 30 μL of each of Example 3, Comparative Example A, and saline was administered four times daily (every 2.5 to 3 hours from morning to evening) using a micropipette into both eyes of albino rabbits (five rabbits per group, n = 10 eyes). The administration period was 12 days, including the day of administration. The corneas were stained with fluorescein and then washed with saline three minutes later. The degree of damage to the corneal surface was observed using SL-17. A corneal damage score was calculated for each group. The results are shown in Figures 13 and 14. Figure 14 shows photographs of corneal damage observed 12 days after the start of administration of no treatment (control), saline, Example 3, or Comparative Example A.

[0086] Repeated administration of 0.1% BAC solution confirmed severe corneal damage. After administration of the BAC solution was completed, the untreated (control) group and the saline-administered group showed gradual recovery from corneal damage. Furthermore, the Comparative Example A-administered group showed a better degree of recovery from corneal damage than the untreated and saline-administered groups. Furthermore, the group administered with Example 3 of the present invention showed a better recovery from corneal damage than either group.

[0087] The results of Test Example 9 suggest that repeated administration of Example 3 results in early recovery from corneal damage.

[0088] The aqueous ophthalmic composition of the present invention, which rapidly thickens at temperatures near body temperature, rapidly gels and remains at the administration site when administered to a living body, thereby maintaining tear fluid on the ocular surface. Furthermore, even when the composition thickens at temperatures above 30°C due to regional or seasonal factors, it can be easily transformed into a highly fluid composition by simply applying a weak force to the composition, eliminating the need for storage in a cool place and making it portable.

Claims

1. An ophthalmic aqueous composition characterized by containing (A) at least two types of methylcellulose, (B) polyethylene glycol, (C) polyvinylpyrrolidone, and (D) citric acid or a pharmaceutically acceptable salt thereof, and gelling.

2. The ophthalmic aqueous composition according to claim 1, wherein the component (A) is two types of methylcellulose.

3. The ophthalmic aqueous composition according to claim 2, wherein the two types of methylcellulose are contained in a mass ratio of 1:30 to 30:

1.

4. The ophthalmic aqueous composition according to any one of claims 1 to 3, wherein the component (A) is methylcellulose having a viscosity of 4 to 400 mPa·s in a 2 w / v% aqueous solution at 20°C.

5. The ophthalmic aqueous composition according to any one of claims 1 to 3, wherein the component (A) is two types selected from the group consisting of methylcellulose having a viscosity of 4 mPa·s, 15 mPa·s, 25 mPa·s, 100 mPa·s, 400 mPa·s, 1500 mPa·s, or 4000 mPa·s in a 2 w / v% aqueous solution at 20°C.

6. The ophthalmic aqueous composition according to any one of claims 1 to 5, wherein the component (B) is at least one selected from the group consisting of PEG8000, PEG4000, PEG800, PEG400, and PEG300.

7. The ophthalmic aqueous composition according to any one of claims 1 to 6, wherein the component (C) is at least one selected from the group consisting of PVP K17, PVP K25, PVP K30, and PVP K90.

8. The ophthalmic aqueous composition according to any one of claims 1 to 7, which is a thermogel artificial tear.

9. An ophthalmic aqueous composition for corneal protection, reduction of corneal epithelial disorders, or recovery of corneal disorders, containing (A) at least two types of methylcellulose, (B) polyethylene glycol, (C) polyvinylpyrrolidone, and (D) citric acid or a pharmaceutically acceptable salt thereof.

10. Use of at least two types of methylcellulose for preparing an ophthalmic aqueous composition for corneal protection, reduction of corneal epithelial disorders, or recovery of corneal disorders, in combination with polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof.